Needham Reiterates Buy on Definitive Healthcare, Maintains $15 Price Target
Portfolio Pulse from richadhand@benzinga.com
Needham analyst Ryan MacDonald has reiterated a 'Buy' rating on Definitive Healthcare (NASDAQ:DH) and maintained a price target of $15.

August 04, 2023 | 9:38 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Definitive Healthcare's stock rating has been reiterated as 'Buy' by Needham analyst Ryan MacDonald, with a maintained price target of $15.
Analyst ratings and price targets can significantly influence investor sentiment and stock price. The reiteration of a 'Buy' rating and a maintained price target by a reputable analyst like Ryan MacDonald from Needham is likely to boost investor confidence in Definitive Healthcare, potentially leading to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100